Id: acc1249
Group: 2sens
Protein: Arix
Gene Symbol: PHOX2A
Protein Id: O14813
Protein Name: PHX2A_HUMAN
PTM: phosphorylation
Site: unclear
Site Sequence:
Disease Category: Cancer
Disease: Neuroblastoma
Disease Subtype:
Disease Cellline: SH-SY5Y
Disease Info:
Drug: PD98059
Drug Info: PD98059 is a selective and cell-permeable inhibitor of MAP kinase kinase (MEK) that blocks the activation of mitogen-activated protein (MAP) kinase by inhibiting MEK1 and MEK2 phosphorylation.
Effect: modulate
Effect Info: MEK1 inhibitors (such as UO126 and PD98059) can reduce the phosphorylation level of Arix/Phox2a.
Note: no tumor effct
Score: 3.0
Pubmed(PMID): 16156742
Sentence Index:
Sentence:

Sequence & Structure:

MDYSYLNSYDSCVAAMEASAYGDFGACSQPGGFQYSPLRPAFPAAGPPCPALGSSNCALGALRDHQPAPYSAVPYKFFPEPSGLHEKRKQRRIRTTFTSAQLKELERVFAETHYPDIYTREELALKIDLTEARVQVWFQNRRAKFRKQERAASAKGAAGAAGAKKGEARCSSEDDDSKESTCSPTPDSTASLPPPPAPGLASPRLSPSPLPVALGSGPGPGPGPQPLKGALWAGVAGGGGGGPGAGAAELLKAWQPAESGPGPFSGVLSSFHRKPGPALKTNLF

No data.

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No data.

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: